Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.38 |
| ▸ | MTOR | P42345 | 4/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.34 |
| ▸ | ATF1 | P18846 | 3/20 | 0.34 |
| ▸ | JUN | P05412 | 2/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 2/20 | 0.33 |
| ▸ | XPO1 | O14980 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | ULK1 | O75385 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29150630 | 0.78 | NFKB1 (0.33) | KDM4ENFKB1ATF1JUNNFKB2 | |
| SCHEMBL27637075 | 0.78 | NFKB1 (0.50) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL4716502 | 0.74 | — | — | |
| SCHEMBL3395853 | 0.74 | CYP1A2 (0.40) | KDM4EPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL14320248 | 0.72 | RXFP1 (0.39) | KDM4EPIK3CAMTORPIK3R1 | |
| SCHEMBL27886744 | 0.72 | BACE1 (0.44) | KDM4EALOX5APFEN1 | |
| SCHEMBL335775 | 0.71 | KDM4E (0.44) | KDM4EPIK3CAPIK3CBMTORPIK3CD | |
| SCHEMBL30107632 | 0.71 | KDM4E (0.44) | KDM4EPIK3CAPIK3CBMTORPIK3CD | |
| SCHEMBL10196960 | 0.71 | KDM4E (0.44) | KDM4EPIK3CAPIK3CBMTORPIK3CD | |
| SCHEMBL6936291 | 0.71 | KDM4E (0.55) | KDM4EPIK3CAPIK3CBMTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1718620-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080350-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | CNR2, CNR1, P2RY2 | KDM4E 2470/4885PIK3CA 333/4885PIK3CB 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.